Steven Lydeamore
Jerry Kanellos
Immuron (ASX:IMC)

Steven Lydeamore

Chief Executive Officer
Immuron (ASX:IMC)

Jerry Kanellos

Chief Operating Officer
Immuron (ASX:IMC)

In this episode, we sit down with Steven Lydeamore, who serves as the Chief Executive Officer and Jerry Kanellos, who serves as Chief Operating Officer of Immuron (ASX:IMC). Join us as we delve into the most recent developments and valuable insights within IMC, and take a closer look at what drives Steven and Jerry’s success.

Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This includes valuable experience in mergers and acquisitions, finance, business development, sales and marketing, manufacturing, and research and development.

Mr. Lydeamore was most recently Chief Executive Officer (CEO) of Anatara Lifesciences Limited (ASX:ANR), during which time the company successfully transitioned from a preclinical to a clinical company following development of a gastrointestinal tract delivery technology from which two products have commenced human clinical trials.

Dr Jerry Kanellos has over twenty years’ experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management, research and development and senior management, and holds a PhD in medicine from the University of Melbourne.

Dr Kanellos has worked as a consultant to the biotechnology industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies, and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.

During his ten years tenure in research and development at CSL Limited, Dr Kanellos gained considerable experience in the drug development process, formulation development through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products.